- Home
- ACST vs BOLT Comparison
ACST vs BOLT Comparison
Compare ACST & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACST
- BOLT
- Stock Information
- Founded
- ACST 2002
- BOLT 2015
- Country
- ACST United States
- BOLT United States
- Employees
- ACST N/A
- BOLT 100
- Industry
- ACST Pharmaceuticals and Biotechnology
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- ACST Health Care
- BOLT Health Care
- Exchange
- ACST Nasdaq
- BOLT Nasdaq
- Market Cap
- ACST 27.2M
- BOLT 25.3M
- IPO Year
- ACST N/A
- BOLT 2021
- Fundamental
- Price
- ACST $3.28
- BOLT $0.64
- Analyst Decision
- ACST Strong Buy
- BOLT Hold
- Analyst Count
- ACST 2
- BOLT 5
- Target Price
- ACST $10.00
- BOLT $1.25
- AVG Volume (30 Days)
- ACST 23.2K
- BOLT 143.6K
- Earning Date
- ACST 11-11-2024
- BOLT 11-07-2024
- Dividend Yield
- ACST N/A
- BOLT N/A
- EPS Growth
- ACST N/A
- BOLT N/A
- EPS
- ACST N/A
- BOLT N/A
- Revenue
- ACST N/A
- BOLT $11,166,000.00
- Revenue This Year
- ACST N/A
- BOLT $16.30
- Revenue Next Year
- ACST N/A
- BOLT N/A
- P/E Ratio
- ACST N/A
- BOLT N/A
- Revenue Growth
- ACST N/A
- BOLT 64.64
- 52 Week Low
- ACST $1.98
- BOLT $0.55
- 52 Week High
- ACST $3.59
- BOLT $1.56
- Technical
- Relative Strength Index (RSI)
- ACST 60.89
- BOLT 48.78
- Support Level
- ACST $3.20
- BOLT $0.62
- Resistance Level
- ACST $3.44
- BOLT $0.68
- Average True Range (ATR)
- ACST 0.17
- BOLT 0.03
- MACD
- ACST 0.01
- BOLT 0.00
- Stochastic Oscillator
- ACST 70.08
- BOLT 47.37
About ACST Acasti Pharma Inc.
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.